Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review

Muscle-specific kinase (MuSK) myasthenia gravis (MG) is relatively rare and has a higher incidence of myasthenic crisis compared with other subtypes. However, there is still a lack of effective treatment for refractory MuSK MG. We report the case of a 70-year-old female MuSK MG patient with recurren...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Frontiers in immunology 2024-11, Vol.15, p.1456822
Hauptverfasser:	Wang, Jia, Zheng, Haotao, Wei, Jia, Wu, Jiaping, Feng, Ziyang, Chen, Xueqin, Liu, Yangsicheng, Qin, Wenxin, Qin, Xiude, Kong, Fanxin
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Autoantibodies - blood Autoantibodies - immunology B-cell depletion therapy B-Lymphocytes - immunology case report Female Humans Immunology Lymphocyte Depletion muscle-specific tyrosine kinase myasthenia gravis Myasthenia Gravis - diagnosis Myasthenia Gravis - drug therapy Myasthenia Gravis - immunology Myasthenia Gravis - therapy Receptor Protein-Tyrosine Kinases - immunology Receptors, Cholinergic - immunology Rituximab - therapeutic use telitacicept Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Muscle-specific kinase (MuSK) myasthenia gravis (MG) is relatively rare and has a higher incidence of myasthenic crisis compared with other subtypes. However, there is still a lack of effective treatment for refractory MuSK MG. We report the case of a 70-year-old female MuSK MG patient with recurrent fluctuations who stabilized on telitacicept in combination with anti-CD20 B-cell depletion therapy. This combination regimen deserves further investigation. Furthermore, we summarized the treatment protocols of 14 previously reported cases of MuSK MG.
ISSN:	1664-3224 1664-3224
DOI:	10.3389/fimmu.2024.1456822